PatientsVisitorsLocations & ServicesAbout the RegionJoin Our TeamPhysicians
Find:  Locations | Services
Pathology and Laboratory Medicine HomeTest and Services CatalogueTransfusion Medicine Product CataloguePolicy and ProcedureJob AidsSpecimen Collection and TransportRequisitionsAntibiogramsGenetic Testing and Molecular GeneticsMicrobiology EssentialsTransfusion EssentialsReference RangesLaboratory SuppliesAcute Care SCM GuidelinesContact InformationPhysician Access to Patient ResultsNew Clinic or Provider Information Changes
Pathology and Laboratory Medicine
Product Catalogue

​Plasma - Solvent Detergent

Transfusion Medicine

  • ​Replacement of plasma coagulation factors or specific plasma proteins in patients who require a high volume of transfusions annually with a diagnosis of:
    • Thrombotic thrombocytopenic purpura (TTP), congenital or acquired, or
    • Hemolytic uremic syndrome (HUS) with associated factor H deficiency, or
    • Clotting factor deficiencies for which specific licenced concentrate may not be readily available ( e.g. factor V, Factor XI, factor XIII)


  • Meet one of the following secondary qualifiers, including those who:
    • Have experienced an allergic reaction to frozen plasma, or
    • Have a pre-existing lung disorder, or
    • Need frozen plasma but a blood group compatible product is not available in a timely manner
​Absolute Contraindications
  • ​IgA deficiency with documented antibodies against IgA
  • Severe Protein S deficiency
​Resource Information

Product Monograph

More Information

Size/Volume Available
  • 200 mL per unit
Pretransfusion Testing Requirements
  • ​ABO Group and Rh Type on current admission
    • Contact Transfusion Medicine/lab prior to collection to confirm

  • Request MUST be approved by the Transfusion Medicine Physician
  • Indicate number of units required and clinical indication
Forms Required


​Alternate Product Names
  • ​Octaplasma
  • ​Solvent-detergent (S/D) treated human plasma
  • Similar in protein composition to frozen plasma, with a reduced content of lipids and lipoprotein as a result of the S/D treatment and purification process
  • S/D treatment reduces the infectious risk of blood-borne viruses (with the exception of non-enveloped viruses, including Parvovirus B-19, Hepatitis A virus)
  • Similar pharmokinetic properties to frozen plasma
  • ​Contains human protein; informed patient consent required for this product
  • Dosing and monitoring should be similar to that of frozen plasma, in adherence with existing SHR policies
  • S/D plasma may be automatically substituted for frozen plasma or cryosupernatant plasma in the setting of plasma exchange by Transfusion Medicine if the requested volume is otherwise unavailable, as an inventory management strategy


​If you choose to print this information, it is valid only on date of print.

Laboratory Controlled Document LSM-889 v5

Last Modified: Monday, October 3, 2022 |
Questions or feedback about this page?